Lundbeck Looks To Pipeline As Generic Competition Hits

14 Aug 2019

• By John Davis

Lundbeck highlighted R&D and the strong growth of four strategic products in the first half, as revenues were hit by generic competitors to top-selling products.

Lundbeck's HQ is in the outskirts of Copenhagen • Source: Shutterstock

The European mid-sized pharmaceutical company Lundbeck Inc. is moving ahead with pivotal Phase III studies of its marketed antidepressant, Rexulti (brexpiprazole, co-developed with Otsuka Holdings Co. Ltd.) in patients with post-traumatic stress disorder (PTSD), as it invests in its “strategic brands” in the face of generic competition to its stalwart, Onfi. The company is also rebuilding its earlier-stage pipeline, exemplified by the Abide Therapeutics Inc. acquisition, completed in early May.

Lundbeck and partner Otsuka expect to start a pivotal Phase III program to evaluate brexpiprazole in combination with sertraline for...